OncoMatch/Clinical Trials/NCT05420948
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
Is NCT05420948 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Carboplatin for head and neck cancer.
Treatment: Pembrolizumab · Carboplatin · Paclitaxel — By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck cancer. Using this blood test, the research team hopes to learn if intermittent (occasional) chemotherapy added to immunotherapy will work better than immunotherapy alone. Participation in this research will last about two years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Exception: Systemic therapy completed more than 3 months prior to signing consent if given as part of multimodal treatment for locally advanced disease is allowed.
Participants should not have had prior systemic therapy administered in the recurrent or metastatic setting. Systemic therapy which was completed more than 3 months prior to signing consent if given as part of multimodal treatment for locally advanced disease is allowed.
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD1(anti-programmed cell death protein1) therapy.
Lab requirements
Blood counts
Participants must have normal organ and marrow function as defined by clinical lab values.
Kidney function
Participants must have normal organ and marrow function as defined by clinical lab values.
Liver function
Participants must have normal organ and marrow function as defined by clinical lab values.
Participants must have normal organ and marrow function as defined by clinical lab values.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify